The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

The FDA has granted Fast Track designation to BW-20805, an investigational small interfering RNA therapy for hereditary angioedema.

Since its discovery in 1998 and winning the Nobel Prize in 2006, ribonucleic acid (RNA) interference has become an invaluable tool for drugmakers to silence disease-causing genes. Nearly three decades ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...

Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...